Human skin replacement - Stratatech

Drug Profile

Human skin replacement - Stratatech

Alternative Names: StrataGraft

Latest Information Update: 19 Jul 2017

Price : $50

At a glance

  • Originator University of Wisconsin System; Wisconsin Alumni Research Foundation
  • Developer Stratatech
  • Class Cell therapies
  • Mechanism of Action Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Burns
  • New Molecular Entity No

Highest Development Phases

  • Phase III Burns
  • Phase II Wounds

Most Recent Events

  • 19 Jul 2017 The US FDA grants Regenerative Medicine Advanced Therapy status to StrataGraft
  • 04 May 2017 Phase-II clinical trials in Wounds in USA (Topical) (NCT03005054)
  • 04 May 2017 Stratatech initiates enrolment in a phase II trial for Burns in USA (NCT03005054)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top